Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KAT7 | O95251 | 1/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441683 | 0.85 | HCRTR2 (0.37) | CHRM1HCRTR2HCRTR1MAPTOPRM1 | |
| Hydrochloric Acid SCHEMBL12989775 | 0.84 | HCRTR2 (0.36) | CHRM1HCRTR2HCRTR1MAPTOPRM1 | |
| SCHEMBL15420479 | 0.84 | CYP46A1 (0.38) | CHRM1HCRTR2KAT5 | |
| SCHEMBL15420465 | 0.75 | DGAT1 (0.38) | HCRTR2 | |
| SCHEMBL15420605 | 0.73 | HDAC1 (0.41) | CHRM1MAPT | |
| SCHEMBL15420260 | 0.72 | KAT5 (0.40) | CHRM1HCRTR2KAT5 | |
| SCHEMBL12989854 | 0.71 | CHRM1 (0.38) | CHRM1KAT5 | |
| SCHEMBL12988790 | 0.71 | CHRM1 (0.42) | CHRM1HCRTR2HCRTR1KAT7KAT5 | |
| SCHEMBL15441476 | 0.71 | CHRM1 (0.42) | CHRM1HCRTR2HCRTR1KAT7KAT5 | |
| SCHEMBL15420674 | 0.71 | CHRM1 (0.38) | CHRM1KAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20070161771-A1 | SYNTHESIS OF ELASTOMERIC CARBORANE-SILOXANES BY HYDROSILATION REACTIONS | THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CHRM1 227/4885HCRTR2 383/4885HCRTR1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.